EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interaction between crizotinib and tropifexor through in vitro and in vivo studies

An Shen, Hailun Xia, Jun Wu, Liang Tao, Jie Chen, HangJuan Lin

PeerJ · 2025

DOI: 10.7717/peerj.20256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von An Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, …. Hauptthemen laut MEDLINE: Crizotinib, Protein Kinase Inhibitors. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ningbo medical and health brand discipline project, Ningbo Traditional Chinese Medicine Pharmaceutical Preparation Center Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the context of cancer treatment, the employment of multiple drug therapies frequently results in a high prevalence of drug-drug interaction (DDI) in clinical practice. Crizotinib is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC). Tropifexor is a Farnesoid X Receptor (FXR) agonist used to treat non-alcoholic steatohepatitis (NASH) and other metabolic disorders. This study developed an ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the quantitative determination of crizotinib and 2-Keto crizotinib concentrations and investigated the effect of tropifexor on crizotinib metabolism. Results showed good linearity for crizotinib and 2-Keto crizotinib in plasma, with the method meeting all quantitative analysis requirements, including selectivity, accuracy, precision, stability, matrix effects, and recovery. In rat liver microsomes (RLM), tropifexor inhibited the metabolism of crizotinib via non-competitive and uncompetitive mechanisms, whereas in human liver microsomes (HLM), the inhibition occured through competitive and non-competitive mechanisms. In vivo studies in rats demonstrated that tropifexor significantly increased the AUC 0−t , AUC 0−∞ , and C max of crizotinib by 35.7%, 36.9%, and 37.5%, respectively, and decreased the CL z/F of crizotinib by 25.2%. For the metabolite 2-Keto crizotinib, tropifexor reduced its CL z/F by 27.9%. Our study developed this UPLC-MS/MS method for the accurate and sensitive quantitative determination of crizotinib and 2-Keto crizotinib concentrations, and elucidated the inhibitory effect of tropifexor on crizotinib metabolism and its inhibitory mechanism. The results of this study will support the necessity of monitoring crizotinib plasma concentrations when used in combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CrizotinibProtein Kinase InhibitorsAnimalsHumansDrug InteractionsTandem Mass SpectrometryRatsMaleMicrosomes, LiverRats, Sprague-DawleyChromatography, High Pressure Liquid

Stichwörter der Autor:innen

CrizotinibMethodologicalPharmacokineticsUPLC-MS/MSVerification

Substanzen

CrizotinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Ningbo Municipal Hospital of Traditional Chinese Medicine (TCM), Affiliated Hospital of Zhejiang Chinese Medical University, Ningbo, Zhejiang, China.
  • Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Förderung

  • Ningbo medical and health brand discipline project
  • Ningbo Traditional Chinese Medicine Pharmaceutical Preparation Center Construction Project

Zitieren

APA

Shen, A., Xia, H., Wu, J., Tao, L., Chen, J., & Lin, H. (2025). Interaction between crizotinib and tropifexor through in vitro and in vivo studies. PeerJ. https://doi.org/10.7717/peerj.20256

Vancouver

Shen A, Xia H, Wu J, Tao L, Chen J, Lin H. Interaction between crizotinib and tropifexor through in vitro and in vivo studies. PeerJ. 2025. doi:10.7717/peerj.20256

BibTeX
@article{Shen2025,
  author = {Shen, An and Xia, Hailun and Wu, Jun and Tao, Liang and Chen, Jie and Lin, HangJuan},
  title = {Interaction between crizotinib and tropifexor through in vitro and in vivo studies},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.20256}
}
Kostenlos starten →